At Zumutor, we make the good better. Our goal is to use next generation antibody technologies to make new biological entities. Our focus is on disease areas that are today’s concerns, mainly in the segments of Oncology. Our interest also lies in Diabetes and Autoimmune Disorders. Our commitment is to create portfolio value for partners, both regional and across the world with biologics that meet international quality standards.
What We Do
We develop therapeutics encompassing recombinant technology-based biosimilars to large antibody structures – the mAbs
We create product portfolios focused on immuno-oncology
We develop new drugs with breakaway potential that will foray into a new realm of improved biologics
Zumutor’s best-in-class labs, combined with state of the art technologies, enable the development of better biologics.
Clients can also avail cell line development, analytical method development and testing, protein characterization, process development, process characterization/scale down validation, and technology transfer services.
Zumutor Biologics Inc. is a niche, innovation driven biologics company registered in the state of Delaware, with its office in Woburn, MA. Expertise and acumen of the Zumutor team is focused on development of new products through patent-pending technology platforms in our state of the art R&D facility in India
Zumutor also offers differentiated services ranging from co-development of monoclonal antibodies to recombinant technology based biosimilars